COMMUNIQUÉS West-GlobeNewswire

Sensei Biotherapeutics Reports Full Year 2024 Financial Results and Update on Clinical Progress
28/03/2025
- Preliminary efficacy data from Phase 1/2 dose expansion cohort show durable responses and tumor shrinkage in a PD-(L)1 resistant “hot” tumor patient population - - Solnerstotug continues to demonstrate a well- [...]
Humacyte Announces Fourth Quarter and Year End 2024 Financial Results and Provides Business Update
28/03/2025
- Received U.S. Food and Drug Administration (FDA) approval of Symvess™ (acellular tissue engineered vessel-tyod) for the treatment of extremity vascular trauma - - Commenced market launch and first commercial sales of [...]
TREMFYA® (guselkumab) receives positive CHMP opinion for treatment of patients with moderately to severely active Crohn’s Disease
28/03/2025
Recommendation based on the findings from the Phase 3 studies (GALAXI programme and GRAVITI) in Crohn’s disease 1 , 2 , 3 Beerse, Belgium (28 March 2025) – Johnson & Johnson today announced that the Committee for [...]
FDA Issues Complete Response Letter for Etripamil for PSVT
28/03/2025
CRL focused on CMC; no clinical issues relating to etripamil raised $69.7M in cash, cash equivalents and short-term investments as of December 31, 2024 MONTREAL and CHARLOTTE, N.C., March 28, 2025 (GLOBE NEWSWIRE) -- [...]
FibroGen Announces Publication of Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer in the Journal of Clinical Oncology
28/03/2025
FG-3246 showed encouraging anti-cancer activity with an acceptable safety profile in patients with metastatic castration-resistant prostate cancer Initiation of Phase 2 monotherapy dose optimization study of FG-3246 in [...]
Bio-Path Holdings Reports Full Year 2024 Financial Results
28/03/2025
Reports Continued Progress Across Both Obesity and Oncology Franchises HOUSTON, March 28, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (OTCQB:BPTH), a biotechnology company leveraging its proprietary DNAbilize ® [...]
CG Oncology Reports 2024 Year End Financial Results and Provides Business Updates
28/03/2025
- Cretostimogene Monotherapy Demonstrated Sustained, Durable Complete Responses in High-Risk Bacillus Calmette Guérin (BCG)-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) - - Initiated CORE-008 Clinical Trial [...]
Verona Pharma Announces Amended Strategic Financing with Oaktree and OMERS
28/03/2025
RIPSA interests repurchased Term loan facility increased to $450 million with more favorable terms Access to up to an additional $200 million LONDON and RALEIGH, N.C., March 28, 2025 (GLOBE NEWSWIRE) -- Verona Pharma [...]
60 Degrees Pharmaceuticals Announces 2024 Annual Results
28/03/2025
FY 2024 net product revenues increased 140% to $607.6 thousand. FY 2024 gross profit increased $443.8 thousand from ($221 thousand) to $222.8 thousand. WASHINGTON, March 28, 2025 (GLOBE NEWSWIRE) -- 60 Degrees [...]
Winstrol Steroid: Benefits, Side Effects, Results & Buy Winstrol Pills Alternatives From CrazyBulk
28/03/2025
NEW YORK, March 28, 2025 (GLOBE NEWSWIRE) -- There exist numerous approaches to enhance muscle growth, a tantalizing prospect for many. However, achieving substantial muscle gains is far from instantaneous. Merely [...]
Ligandrol (LGD-4033) SARMs: Benefits, Results & Buy Ligandrol Pills Alternatives From CrazyBulk
28/03/2025
NEW YORK, March 28, 2025 (GLOBE NEWSWIRE) -- A significant portion of the populace leads lifestyles that compromise both cognitive and physical functionality. Prioritizing a healthy lifestyle is paramount for optimal [...]
ProvaDent Reviews (Is It Safe And Legit?) Investigative Report On Ingredients, Side Effects, And Benefits!
28/03/2025
TALLMADGE, Ohio, March 28, 2025 (GLOBE NEWSWIRE) -- ProvaDent is precisely fabricated to support oral health by promoting a balanced oral microbiome. It works to encourage the growth of beneficial bacteria while [...]
Pharming Group to participate in April investor conferences
28/03/2025
Leiden, the Netherlands, March 28, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following investor conferences in the month [...]
Dupixent® (dupilumab) Approved as the First-ever Biologic Medicine in Japan for Patients with Chronic Obstructive Pulmonary Disease (COPD)
28/03/2025
Following recent approvals in the EU, China and the U.S., this approval was based on pivotal Phase 3 results in adults with elevated eosinophils Approval marks the first new treatment approach for COPD in more than a [...]
Press Release: Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD
28/03/2025
Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD Following recent approvals in the EU, China, and the US, this approval was based on pivotal phase 3 results in adults with elevated [...]
Communiqué de presse : Le Dupixent devient le tout premier biomédicament approuvé au Japon pour le traitement de la BPCO
28/03/2025
Le Dupixent devient le tout premier biomédicament approuvé au Japon pour le traitement de la BPCO Cette approbation fait suite à celle obtenue récemment dans l’Union européenne, en Chine et aux États-Unis et repose sur [...]
Curium Completes the Acquisition of Monrol as Part of its Plan to Significantly Expand Lutetium-177 Capacity and PET Footprint
28/03/2025
Positions Curium as leading manufacturer of Lu-177 isotope Brings innovative R&D expertise and pipeline to Curium Enhances Curium’s SPECT & PET geographical coverage and supply chain PARIS, March 28, 2025 (GLOBE [...]
DBV Technologies Announces Financing of up to $306.9 Million (€284.5 Million) to Advance Viaskin® Peanut Patch Through Biologics License Application Submission and U.S. Commercial Launch, if Approved
28/03/2025
Châtillon, France, March 27, 2025 DBV Technologies Announces Financing of up to $306.9 Million (€284.5 Million) to Advance Viaskin® Peanut Patch Through Biologics License Application Submission and U.S. Commercial [...]
DBV Technologies Annonce un Financement pouvant atteindre 306,9 millions de dollars (284,5 millions d’euros) permettant d’avancer le programme Viaskin® Peanut jusqu’au dépôt d'une Demande de Licence Biologique (BLA) et d’assurer la...
28/03/2025
Châtillon, France, le 28 mars (3h30 CET) 2025 DBV Technologies Annonce un Financement pouvant atteindre 306,9 millions de dollars (284,5 millions d’euros) permettant d’avancer le programme Viaskin® Peanut jusqu’au dépôt [...]

Pages